Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
What is the Skeletal System?01:02

What is the Skeletal System?

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study.

Journal of bone and mineral metabolism·2026
Same author

Unexpected [18F]-fluciclovine hyperuptake in radiation necrosis after proton therapy: illustrative case.

Journal of neurosurgery. Case lessons·2026
Same author

Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026
Same author

Impact of physical and chemical parameters on spinoculation for chimeric antigen receptor T cell manufacturing using a quality-by-design approach.

Molecular therapy. Advances·2026
Same author

A carotid web with accumulation of myofibroblasts: a case report.

BMC neurology·2026
Same author

Palopegteriparatide in Japanese adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway Japan trial.

Endocrine journal·2025
Same journal

[The frontier of adipocyte biology, cold environment induces thermogenic genes via epigenomic switch.]

Clinical calcium·2019
Same journal

[Sequential treatment of osteoporosis with anti-sclerostin.]

Clinical calcium·2019
Same journal

[The sequential therapy of romosozumab followed by denosumab for osteoporosis.]

Clinical calcium·2019
Same journal

[Wnt signaling in myeloma.]

Clinical calcium·2019
Same journal

[Fate decision of hematopoietic stem cells by Wnt signaling.]

Clinical calcium·2019
Same journal

[Control of inflammatory bone destruction by targeting the Wnt signaling pathway.]

Clinical calcium·2019
See all related articles

Related Experiment Videos

[Do thiazolidinediones harm skeletal integrity?].

Yasuhiro Takeuchi1

  • 1Toranomon Hospital Endocrine Center.

Clinical Calcium
|May 1, 2008
PubMed
Summary
This summary is machine-generated.

Thiazolidinediones (TZDs) improve glucose metabolism in type 2 diabetes but may reduce bone formation. Prescribing TZDs, especially to older women, warrants caution due to potential fracture risks.

Related Experiment Videos

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Bone Biology

Background:

  • Thiazolidinediones (TZDs) are insulin-sensitizing drugs commonly used for type 2 diabetes mellitus.
  • TZDs activate peroxisome proliferator-activated receptor gamma (PPAR-gamma), influencing cellular differentiation and glucose metabolism.
  • Concerns exist regarding TZDs' potential negative impact on bone health, evidenced by inhibited osteoblastogenesis and increased fracture risk in some patient populations.

Purpose of the Study:

  • To evaluate the implications of Thiazolidinedione (TZD) use in type 2 diabetes patients, focusing on potential adverse effects on bone metabolism.
  • To assess the clinical relevance of TZD-induced changes in adipogenesis and osteoblastogenesis.
  • To determine if TZD therapy poses a significant fracture risk, particularly in vulnerable patient groups like postmenopausal women.

Main Methods:

  • Review of existing literature on Thiazolidinedione (TZD) mechanisms of action, including PPAR-gamma activation.
  • Analysis of studies investigating TZD effects on bone marrow stromal cells, adipogenesis, and osteoblastogenesis.
  • Examination of clinical data correlating TZD treatment (e.g., rosiglitazone) with fracture incidence in type 2 diabetes patients.

Main Results:

  • Thiazolidinediones (TZDs) stimulate adipogenesis while inhibiting osteoblastogenesis in bone marrow stromal cells, suggesting a potential mechanism for reduced bone formation.
  • Clinical reports indicate a higher incidence of fractures in female type 2 diabetes patients treated with rosiglitazone compared to metformin.
  • These findings highlight a potential detrimental effect of TZDs on bone health.

Conclusions:

  • The observed effects of Thiazolidinediones (TZDs) on bone metabolism warrant careful consideration, particularly in patients with pre-existing fracture risks.
  • Prescribing TZDs to patients with type 2 diabetes, especially older women, requires a thorough risk-benefit assessment due to potential negative impacts on bone.
  • Further research is needed to fully elucidate the long-term skeletal consequences of TZD therapy.